产品描述
说明书
相关产品
相关论文
产品问答
|
|
| 发货规格 | 1×10⁶ |
| 别名 | CCRF/CEM, CCRFCEM, CCRF.CEM, CCRF CEM, CCRF, CEM, CEM-CCRF, CEM-CCRF (CAMR), CCRF/CEM/0, CEM/0, CEM-0, CCRF-CEM/S, GM03671, GM03671C |
| 形态 | 淋巴母细胞样 |
| 生长特性 | 悬浮 |
| 培养条件 | RPMI-1640+10%FBS+1%P/S |
| 冻存条件 | 90%FBS+10%DMSO |
| 传代方式 | 离心 |
| 倍增时间 | 24~30h |
| 传代比例 | 维持细胞浓度在1x105~1x106个/ml |
| 换液频率 | 每周2~3次 |
| 生物安全等级 | 1 |
|
|
| 种属 | 人源 |
| 组织来源 | 血液 |
| 肿瘤类型 | 急性淋巴细胞白血病 |
| 供体信息 | 4岁高加索女性 |
| 背景描述 | CRF-CEM细胞是一种通常用于免疫肿瘤学和免疫学研究的人类T淋巴母细胞。这些细胞是从一名患有急性淋巴细胞白血病(ALL)的4岁白人女性的外周血中分离出来的。 |
|
|
| 蛋白表达 | p53 negative |
| 同工酶 | ADA, 1ES-D, 1G6PD, BGLO-I, 1PEP-D, 1PGD, CPGM1, 1PGM3, 0 |
| 基因表达 | CD3; Homo sapiens, expressed ,CD5; Homo sapiens, expressedCD7; Homo sapiens, expressed, CD4; Homo sapiens, expressed |
| 致瘤性 | 叙利亚仓鼠 |
| 抗原表达 | CD3 B (37%), CD4 (50%), CD5 (95%), CD7 (77%) |
| 病毒 | EBV ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-1/2 -, MLV -, SMRV -negative |
| 逆转录酶 | 阴性 |
| 核型 | modal number = 47; range = 41 to 95.Fifty karyotypes showed no consistent loss or gain of particular chromosomes. Twenty-eight percent of the cells with 45 chromosomes were C-; 53% of all cells had an extra D and 35% had an extra F. Only N1 and N18 were not affected by gain or loss. No marker chromosomes noted. |
STR鉴定
STR位点信息
| Amelogenin | X |
| CSF1PO | 9,10,11 (RCB=RCB1980) 10,11 (AddexBio=C0003001/32; ATCC=CCL-119; Cosmic-CLP=905952; KCLB=10119; PubMed=20922763) 10,11,12 (JCRB=IFO50412; JCRB=JCRB9023) 10,13 (ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240) 11 (ECACC=85112105; JCRB=JCRB0033; PubMed=19372543) |
| D2S1338 | 23,24 (DSMZ=ACC-240) 24 (ATCC=CCL-119; PubMed=19372543; PubMed=20922763) |
| D3S1358 | 14,15 (CLS=300147; DSMZ=ACC-240; KCLB=10119) 15 (ATCC=CCL-119; PubMed=19372543) 15,16 (PubMed=20922763) |
| D5S818 | 12,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980) 12,13,14 (Cosmic-CLP=905952) |
| D7S820 | 9,12 (JCRB=JCRB0033) 9,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980) |
| D8S1179 | 12,13 (CLS=300147; DSMZ=ACC-240; PubMed=20922763) 13 (ATCC=CCL-119; PubMed=19372543) |
| D13S317 | 10,11,12 (RCB=RCB1980) 11 (ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240) 11,12 (AddexBio=C0003001/32; ATCC=CCL-119; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763) |
| D16S539 | 10,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; PubMed=19372543; PubMed=20922763) 10,13,14 (RCB=RCB1980) |
| D18S51 | 13 (DSMZ=ACC-240) 13,18 (ATCC=CCL-119; CLS=300147) |
| D19S433 | 14,15 |
| D21S11 | 30,33.2 (ATCC=CCL-119; PubMed=19372543; PubMed=20922763) 30,34.2 (CLS=300147; DSMZ=ACC-240) |
| FGA | 22,23,24,25 (DSMZ=ACC-240) 23,24 (ATCC=CCL-119; CLS=300147; PubMed=20922763) 24 (PubMed=19372543) |
| Penta D | 10,11 (CLS=300147; DSMZ=ACC-240) 11 (ATCC=CCL-119) |
| Penta E | 5 (DSMZ=ACC-240) 5,14 (ATCC=CCL-119; CLS=300147) |
| TH01 | 6,7 |
| TPOX | 7,8 (DSMZ=ACC-240) 8 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980) |
| vWA | 17,18,19 (DSMZ=ACC-240) 17,19 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763) 18,19 (RCB=RCB1980) |
热门产品推荐